Evexomostat — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 2mo
ESTIMATED |
READOUT
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K A
Phase 1/2 · HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer |
SynDevRx, Inc. | Evexomostat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|